The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide

Cancer Immunology, Immunotherapy

Volumn 61, Issue 4, 2012, Pages 469-480

  Zacarías Fluck, Mariano F ^a,b   Hess, Leonardo ^a   Salatino, Mariana ^c   Croci, Diego O ^c   Stupirski, Juan C ^c   Di Masso, Ricardo J ^a   Roggero, Eduardo ^a   Rabinovich, Gabriel A ^c,d   Scharovsky, O Graciela ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Aggressiveness; Cyclophosphamide; Galectin 1; Lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; GALECTIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; GROWTH RATE; IN VIVO STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; T CELL LYMPHOMA; TREATMENT RESPONSE;

ANIMALS; ANTIGENS, CD4; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GALECTIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOMA, T-CELL; MICE; NEOPLASM METASTASIS; T-LYMPHOCYTES, REGULATORY;

EID: 84862496519     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1114-3     Document Type: Article

References (49)

1. Non-Hodgkin Lymphoma, The Leukemia & Lymphoma Society. http://www.leukemia-lymphoma.org
2. Fisher SG, Fisher RI (2004) The epidemiology of non-Hodgkin's lymphoma. Oncogene 23:6524-6534 (Pubitemid 39265515)
3. Camby I, Le Mercier M, Lefranc F, Kiss R (2006) Galectin-1: a small protein with major functions. Glycobiology 16:137R-157R (Pubitemid 44530693)
4. He J, Baum LG (2006) Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell trans-endothelial migration. Lab Invest 86:578-590 (Pubitemid 43780439)
5. Van der Leij J, van den Berg A, Harms G, Eschbach H, Vos H, Zwiers P, van Weeghel R, Groen H, Poppema S, Visser L (2007) Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol Immunol 44:506-513 (Pubitemid 44287047)
6. Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, Geffner JR, Rabinovich GA (2009) Tolerogenic signals delivered by dendritic cells to T cells through a galectin- 1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 10:981-991
7. Garin MI, Chu C-C, Golshayan D, Cernuda-Morollón E, Wait R, Lechler RI (2007) Galectin-1: a key effector of regulation mediated by CD4 ? CD25 ? T cells. Blood 109:2058-2065 (Pubitemid 46348206)
8. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Zwirner NW, Hernandez JD, Poirier F, Riley EM, Baum LG, Rabinovich GA (2007) Differential glycosylation of Th1, Th2 and Th17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8:825-834 (Pubitemid 47099035)
9. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection. A potential mechanism of tumor-immune privilege. Cancer Cell 5:241-251 (Pubitemid 38402116)
10. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA (2007) The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 104:13134-13139 (Pubitemid 351737605)
11. Rodig SJ, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg DS, Rabinovich GA, Shipp MA, Kutok JL (2008) AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res 14:3338-3344
12. Kuo PL, Hung JY, Huang SK, Chou SH, Cheng DE, Jong YJ, Hung CH, Yang CJ, Tsai YM, Hsu YL, Huang MS (2011) Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol 186:1521-1530
13. Banh A, Zhang J, Cao H, Bouley DM, Kwok S, Kong C, Giaccia AJ, Koong AC, Le QT (2011) Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 71:4423-4431
14. Mathieu V, Le Mercier M, De Neve N, Sauvage S, Gras T, Roland I, Lefranc F, Kiss R (2007) Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 127:2399-2410 (Pubitemid 47619747)
15. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, Mathieu V (2008) Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229:172-183
16. Zacarias Fluck MF, Rico MJ, Gervasoni SI, Ilarregui JM, Toscano MA, Rabinovich GA, Scharovsky OG (2007) Low-dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model. Cancer Immunol Immunother 56:237-248 (Pubitemid 44833097)
17. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P (2007) Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 67:3970-3975 (Pubitemid 46762187)
18. Furukawa H, Iwata R, Moriyama N (2001) Growth rate of pancreatic adenocarcinoma: initial clinical experience. Pancreas 22:366-369 (Pubitemid 32402085)
19. Kuroishi T, Tominaga S, Morimoto T, Tashiro H, Itoh S, Watanabe H, Fukuda M, Ota J, Horino T, Ishida T, Yokoe T, Enomoto K et al (1990) Tumor growth rate and prognosis of breast cancer mainly detected by mass screening. Jpn J Cancer Res 81:454-462 (Pubitemid 20207750)
20. Shackney SE, McCormack GW, Cuchural GJ (1978) Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann Intern Med 89:107-121 (Pubitemid 8365450)
21. Spratt JS, Spratt TL (1964) Rates of growth of pulmonary metastases and host survival. Ann Surg 159:161-171
22. Szereday Z, Schally AV, Nagy A, Plonowski A, Bajo AM, Halmos G, Szepeshazi K, Groot K (2002) Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215. Br J Cancer 86:1322-1327
23. Usuda K, Saito Y, Sagawa M, Sato M, Kanma K, Takahashi S, Endo C, Chen Y, Sakurada A, Fujimura S (1994) Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 74:2239-2244 (Pubitemid 24322277)
24. Bajzer Z (1999) Gompertzian growth as a self-similar and allometric process. Growth Dev Aging 63:3-11
25. Collins VP, Loeffler RK, Tivey H (1956) Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 76:988-1000
26. Scharovsky OG, Celoria GC, Racca AL, Font MT (1991) Association between immune response and body conformation in the mouse (Mus musculus). Rev Brasil Genet 14:373-380
27. Tang Q, Bluestone JA (2008) The Foxp3 + regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9:239-244 (Pubitemid 351267321)
28. Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG (2007) Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 56:1687-1700 (Pubitemid 47313090)
29. Demydenko D, Berest I (2009) Expression of galectin-1 in malignant tumors. Exp Oncol 31:74-79
30. Mather K (1953) The genetical structure of populations. Symp Soc Exp Biol 7:66-95
31. Skibinski DOF, Thoday JM (1979) Disruptive selection with fixed optima. Heredity 42:327-335
32. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296 (Pubitemid 46697910)
33. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F et al (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103:15975-15980 (Pubitemid 44657577)
34. Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S (2006) Lack of suppressive CD4 + CD25 + FOXP3 + T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 126:2217-22123
35. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 107:301-304 (Pubitemid 43053555)
36. Gandhi MK, Moll G, Smith C, Dua U, Lambley E, Ramuz O, Gill D, Marlton P, Seymour JF, Khanna R (2007) Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 110:1326-1329 (Pubitemid 47281432)
37. Demers M, Couillard J, Giglia-Mari G, Magnaldo T, St-Pierre Y (2009) Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation. Biochem Biophys Res Commun 387:425-429
38. Demers M, Biron-Pain K, Hébert J, Lamarre A, Magnaldo T, St- Pierre Y (2007) Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model. Cancer Res 67:2824-2829 (Pubitemid 46548972)
39. St-Pierre Y, Aoudjit F, Lalancette M, Potworowski EF (1999) Dissemination of T cell lymphoma to target organs: a posthoming event implicating ICAM-1 and matrix metalloproteinases. Leuk Lymphoma 34:53-61 (Pubitemid 29248659)
40. Matar P, Rozados VR, González AD, Dlugovitzky DG, Bonffl RD, Scharovsky OG (2000) Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur J Cancer 36:1060-1066 (Pubitemid 30316433)
41. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG (2001) Downregulation of T-cell derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol 1:307-319 (Pubitemid 32183729)
42. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG (2002) Th2/ Th1 switch induced by a single-low dose cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50:588-596 (Pubitemid 34045258)
43. Blaser C, Kaufmann M, Müller C, Zimmermann C, Wells V, Mallucci L, Pircher H (1998) β-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol 28:2311-2319 (Pubitemid 28362706)
44. Zuñiga E, Rabinovich GA, Iglesias MM, Gruppi A (2001) Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. J Leukoc Biol 70:73-79 (Pubitemid 32613665)
45. Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C, Kiss R (2008) The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/ or responses to therapy. Oral Oncol 44:86-93 (Pubitemid 350251284)
46. Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, André S, Gabius HJ, Laurent G (2008) Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 18:705-712 (Pubitemid 352009927)
47. Kamper P, Ludvigsen M, Bendix K, Hamilton-Dutoit S, Rabinovich GA, Møller MB, Nyengaard JR, Honoré B, d'Amore F (2011) Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood 117:6638-6664
48. Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F (2010) Galectins and gliomas. Brain Pathol 20:17-27
49. Verschuere T, De Vleeschouwer S, Lefranc F, Kiss R, Van Gool SW (2011) Galectin-1 and immunotherapy for brain cancer. Expert Rev Neurother 11:533-543